Vimian Group AB (publ) (VIMIAN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Vimeon Group Q3 Report 2025 presentation. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now, I will hand the conference over to the speakers, CFO and Interim CEO Karl-Johan Zetterberg-Baudry and Magnus Schellberg, Vimeon Specialty Pharma. Please go ahead. Good morning, everyone, and welcome to Vimeon's third quarter earnings call. I'm Kaliwan Sattabaibodri, CFO and Interim CEO, and with me today is Magnus Kjellberg, who's leading Specialty Pharma, our largest segment representing almost 50% of Indian. We'll go through the quarterly results, and Magnus will give you some additional insights to our Specialty Pharma segment. We deliver strong revenue growth of 19%, with 9% organic growth in the third quarter. We also saw strong earnings growth with adjusted EBITDA up 17% in the quarter. Both specialty pharma and veterinary services continue to deliver strong performance, and our medtech segment returned to organic growth in the quarter after a tougher second quarter this year. In August, we received the positive news in the US indemnification dispute. The court awarded us $40.2 million in damages, which means that we're entitled to compensation exceeding the amount we paid in the settlement with deficiencies in 2023. Our M&A pipeline continues to build, and we're working hard to progress key targets in the pipeline. Turning to the numbers, And looking at the past years, Veeman has a strong track record of growth and profitability with 16% compounded annual revenue growth and 14% adjusted EBITDA CAGR between 2022 and the third quarter of 2025. For the third quarter isolated, we reported 19% total revenue growth reaching 104.3 million euros. Organic growth in the quarter wa...